Cargando…
Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
SIMPLE SUMMARY: Although the incorporation of immune checkpoint inhibitors (ICIs) in melanoma treatment has significantly improved prognosis for patients with advanced disease, a substantial proportion of patients have limited clinical benefit from ICIs’ administration. Except for the well-studied P...
Autores principales: | Ziogas, Dimitrios C., Theocharopoulos, Charalampos, Lialios, Panagiotis-Petros, Foteinou, Dimitra, Koumprentziotis, Ioannis-Alexios, Xynos, Georgios, Gogas, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216291/ https://www.ncbi.nlm.nih.gov/pubmed/37345056 http://dx.doi.org/10.3390/cancers15102718 |
Ejemplares similares
-
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021) -
An overview of antibody–drug conjugates in oncological
practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020) -
Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review
por: Ziogas, Dimitrios C., et al.
Publicado: (2021) -
The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023) -
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
por: Le Mercier, Isabelle, et al.
Publicado: (2015)